• Please log in or register to access this feature.

SYSTEMATIC REVIEW

You have free access to this content

Systematic review: faecal transplantation for the treatment of Clostridium difficile-associated disease

  1. B. Guo1,*,
  2. C. Harstall1,
  3. T. Louie2,
  4. S. Veldhuyzen van Zanten3,
  5. L. A. Dieleman3

Article first published online: 23 FEB 2012

DOI: 10.1111/j.1365-2036.2012.05033.x

Issue

Alimentary Pharmacology & Therapeutics

Alimentary Pharmacology & Therapeutics

Volume 35, Issue 8, pages 865–875, April 2012

Additional Information

How to Cite

Guo, B., Harstall, C., Louie, T., Veldhuyzen van Zanten, S. and Dieleman, L. A. (2012), Systematic review: faecal transplantation for the treatment of Clostridium difficile-associated disease. Alimentary Pharmacology & Therapeutics, 35: 865–875. doi: 10.1111/j.1365-2036.2012.05033.x

Author Information

  1. 1

    Institute of Health Economics, Edmonton, Alberta, Canada

  2. 2

    Departments of Microbiology, Immunology and Infectious Diseases, University of Calgary, Calgary, Alberta, Canada

  3. 3

    Division of Gastroenterology, University of Alberta, Edmonton, Alberta, Canada

*Correspondence to:
Dr B. Guo, Health Technology Assessment Unit, Institute of Health Economics, 10405-Jasper Avenue, Edmonton, Alberta, CanadaT5J 3N4.
E-mail: bguo@ihe.ca

  1. This uncommissioned systematic review article was subject to full peer-review.

Publication History

  1. Issue published online: 21 MAR 2012
  2. Article first published online: 23 FEB 2012
  3. Manuscript Accepted: 27 JAN 2012
  4. Manuscript Revised: 25 JAN 2012
  5. Manuscript Revised: 8 JAN 2012
  6. Manuscript Received: 19 DEC 2011

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (153K)

References

  • 1
    McKibben L, Horan T, Tokars JI, et al. Guidance on public reporting of healthcare-associated infections: recommendations of the healthcare infection control practices advisory committee. Am J for Infect Control 2005; 33: 217–26.
  • 2
    McFarland LV, Beneda HW, Clarridge JE, Raugi GJ. Implications of the changing face of Clostridium difficile disease for health care practitioners. Am J Infect Control 2007; 35: 237–53.
  • 3
    Carter GP, Rood JI, Lyras D. The role of toxin A and toxin B in Clostridium difficile-associated disease: Past and present perspectives. Gut Microbes 2010; 1: 58–64.
  • 4
    Kelly CP, Lamont JT. Clostridium difficile - more difficult than ever. N Engl J Med 2008; 359: 1932–40.
  • 5
    Gravel D, Gardam M, Taylor G, et al. Infection control practices related to Clostridium difficile infection in acute care hospitals in Canada. AJIC 2009; 37: 9–14.
  • 6
    Hookman P, Barkin JS. Clostridium difficile associated infection, diarrhea and colitis. World J Gastroenterol 2009; 15: 1554–80.
  • 7
    Gravel D, Miller M, Clostridium difficile Surveillance Working Group. Clostridium Difficile Associated Diarrhea in Acute-Care Hospitals Participating in CHISP: November 1, 2004 to April 30, 2005. Montreal PQ: Canadian Nosocomial Infection Surveillance Program (CNISP.PCSIN), 2007.
  • 8
    Pepin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 2005; 173: 1–6.
  • 9
    Elixhauser A, Jhung M. Clostridium Dillicile-Associated Disease in U.S. Hospitals, 1993-2005. Rockville MD: Agency for Healthcare Research and Quality (AHRQ), 2008.
  • 10
    Poutanen SM, Simor AE. Clostridium difficile-associated diarrhea in adults. CMAJ 2004; 171: 51–8.
  • 11
    Owens Jr RC, Donskey CJ, Gaynes RP, Loo VG, Muto CA. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 2008; 46(Suppl 1): S19–31.
  • 12
    Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile - associated diarrhea with high morbidity and mortality. N Eng J Med 2005; 353: 2442–50.
  • 13
    Rodemann JF, Dubberke ER, Reske KA, Seo DH, Stone CD. Incidence of Clostridium difficule infection in inflammatory bowel disease. Clin Gastroenterol and Hepatol 2007; 5: 339–44.
  • 14
    Health Canada. C. difficile (Clostridium difficile). Available at: http://www.hc-sc.gc.ca/hl-vs/iyh-vsv/diseases-maladies/cdifficile-eng.php. Accessed September 2, 2010.
  • 15
    Public Health Agency of Canada. Fact sheet - Clostridium difficile (C. difficile). Available at: http://www.phac-aspc.gc.ca/id-mi/cdiff-eng.php. Accessed January 13, 2010.
  • 16
    Calfee DP. Clostridium difficile: a reemerging pathogen. Geriatrics 2008; 63: 10–14, 21.
  • 17
    Lamont JT. Clostridium difficile colitis. European Surgery - Acta Chirurgica Austriaca 2004; 36: 161–5.
  • 18
    Bakken JS. Fecal bacteriotherapy for recurrent Clostridium difficile infection. Anaerobe 2009; 15: 285–9.
  • 19
    McFee RB, Abdelsayed GG. Clostridium difficile. Dis Mon 2009; 55: 439–70.
  • 20
    Brandt LJ, Borody TJ, Campbell J. Endoscopic fecal microbiota transplantation: “first-line” treatment for severe Clostridium difficile infection? J Clin Gastroenterol 2011; 45: 655–7.
  • 21
    Cocanour CS. Best strategies in recurrent or persistent Clostridium difficile infection. Surgical Infections 2011; 12: 235–9.
  • 22
    Bartlett JG. Clostridium difficile: progress and challenges. Ann N Y Acad Sci 2010; 1213: 62–9.
    Direct Link:
  • 23
    KuoLee R, Chen W. Non-antibiotic strategies for the prevention/treatment of Clostridium difficile infection. Expert Opinion on Therapeutic Patents 2008; 18: 1395–403.
  • 24
    Bauer MP, van Dissel JT. Alternative strategies for Clostridium difficile infection. Int J Antimicrob Agents 2009; 33(Suppl 1): S51–6.
  • 25
    Bauer MP, Kuijper EJ, van Dissel JT. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect 2009; 15: 1067–79.
    Direct Link:
  • 26
    Bartlett JG. Narrative review: the new epidemic of clostridium difficile - associated Enteric disease. Ann Intern Med 2006; 145: 758–64.
  • 27
    Johnson S. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J Infect 2009; 58: 403–10.
  • 28
    Leffler DA, Lamont JT. Treatment of Clostridium difficile-associated disease. Gastroenterology 2009; 136: 1899–912.
  • 29
    Monaghan T, Boswell T, Mahida YR. Recent advances in Clostridium difficile-associated disease. Postgrad Med J 2009; 85: 152–62.
  • 30
    van Nispen tot Pannerden CM, Verbon A, Kuipers EJ. Recurrent Clostridium difficile infection. What are the Treatment Options? Drugs 2011; 71: 853–68.
  • 31
    Macconnachie AA, Fox R, Kennedy DR, Seaton RA. Faecal transplant for recurrent Clostridium difficile-associated diarrhoea: a UK case series. QJM 2009; 102: 781–4.
  • 32
    Surawicz CM. Treatment of recurrent Clostridium difficile-associated disease. Nat Clin Pract Gastroenterol Hepatol 2004; 1: 32–8.
  • 33
    Surawicz CM, Alexander J. Treatment of refractory and recurrent Clostridium difficile infection. Nature Reviews Gastroenterology & Hepatology 2011; 8: 330–9.
  • 34
    Borody TJ, Warren EF, Leis SM, Surace R, Ashman O, Siarakas S. Bacteriotherapy using fecal flora: toying with human motions. J Clin Gastroenterol 2004; 38: 475–83.
  • 35
    Landy J, Al-Hassi HO, McLaughlin SD, et al. Review article: faecal transplantation therapy for gastrointestinal disease. Aliment Pharmacol Ther 2011; 34: 409–15.
    Direct Link:
  • 36
    Guo B, Nguyen T, Ohinmaa A, Harstall C. Fecal transplantation for the treatment of Clostridium difficule-associated disease or ulcerative colitis. Edmonton AB: Institute of Health Economics, 2011.
  • 37
    Cook DJ, Mulrow CD, Haynes RB. Systematic reviews: synthesis of best evidence for clinical decisions. Ann Intern Med 1997; 126: 376–80.
  • 38
    Chambers D, Rodgers M, Woolacott N. Not only randomized controlled trials, but also case series should be considered in systematic reviews of rapidly developing technologies. J Clin Epidemiol 2009; 62: 1253–60.
  • 39
    Young J, Fry-Smith A, Hyde C. Lung volume reduction surgery (LVRS) for chronic obstructive pulmonary disease (COPD) with underlying severe emphysema. Thorax 1999; 54: 779–89.
  • 40
    Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 2003; 36: 580–5.
  • 41
    Garborg K, Waagsbo B, Stallemo A, Matre J, Sundoy A. Results of faecal donor instillation therapy for recurrent Clostridium difficile-associated diarrhoea. Scand J Infect Dis 2010; 42: 857–61.
  • 42
    Mellow MH, Kanatzar A. Colonoscopic fecal bacteriotherapy in the treatment of recurrent Clostridium difficile infection–results and follow-up. J Okla State Med Assoc 2011; 104: 89–91.
  • 43
    Rohlke F, Surawicz CM, Stollman N. Fecal flora reconstitution for recurrent Clostridium difficile infection: results and methodology. J Clin Gastroenterol 2010; 44: 567–70.
  • 44
    Yoon SS, Brandt LJ. Treatment of refractory/recurrent C. difficile-associated disease by donated stool transplanted via colonoscopy: a case series of 12 patients. J Clin Gastroenterol 2010; 44: 562–6.
  • 45
    Silverman MS, Davis I, Pillai DR. Success of self-administered home fecal transplantation for chronic Clostridium difficile infection. Clin Gastroenterol & Hepatol 2010; 8: 471–3.
  • 46
    Louie T, Louie M, Krulicki W, Byrne B, Ward L. Home-based fecal flora infusion to arrest multiply-recurrent Clostridium difficile infection (CDI) . 48th Annual ICAAC/IDSA 46th Annual Meeting Abstract No. K-4201, 579, 2008.
  • 47
    Borody TJ, Wettstein AR, Leis S, Hills LA, Campbell J, Torres M. Clostridium difficile complicating inflammatory bowel disease: Pre- and post-treatment findings. Gastroenterology 2008; 1344(Suppl. 1): A-361.
  • 48
    Kassam Z, Hundal R, Marshall J, Lee CH. Fecal transplantation via retention enema is effective for recurrent or refractory Clostridium difficile-associated diarrhea. Digestive Disease Week ePosters Archives, S1223. 2010.
  • 49
    Nieuwdorp M, Van Nood E, Speelman P, et al. Treatment of recurrent Clostridium difficile-associated diarrhoea with a suspension of donor faeces. Ned Tijdschr Geneeskd 2008; 152: 1927–32.
  • 50
    Faust G, Langelier D, Hadded H, Menard DB. Treatment of recurrent pseudomembranous colitis (RPMC) with stool transplantation (ST): report of six cases. Can J Gastroenterol 2002; 16(Suppl. SA): A43.
  • 51
    Borody TJ, Leis Sm, Chongnan J, et al. Faecal bacteriotherapy (FB) for chronic C. difficile (Cd) syndromes. J Gastroenterol Hepatol 2003; 18(Suppl): B8.
  • 52
    Wettstein A, Borody TJ, Leis S, Chongnan J, Torres M, Hills LA. Fecal bacteriotherapy-an effective treatment for relapsing symptomatic Clostridium difficile infection. Gut 2007; 56(Suppl III): A303.
  • 53
    Arkkila PE, Uusitalo-Seppala R, Lehtola L, Moilanen V, Ristikankare M, Mattila EJ. Fecal bacteriotherapy for recurrent Clostridium difficile infection. Digestive Disease Week, New Orleans, LA USA. Conference Publication 2010; 138(Suppl. 1): S5.
  • 54
    Wilcox GM. Early experience with a Fecal Bacteriotherapy (FB) program for recurrent and C-difficile infection (CDI). Digestive Disease Week, Chicago, IL, USA. Conference Publication 2011; 140(Suppl. 1): S361.
  • 55
    Kelly C, de Leon L. Successful treatment of recurrent Clostridium difficile infection with donor stool administered at colonoscopy: a case series. Am J Gastroenterol 2010; 105: S135.
  • 56
    NHS Centre for Reviews and Dissemination. Undertaking systematic reviews of research on effectiveness. CRD's guidance for those carrying out or commissioning reviews, 2nd ed. York: York Publishing Services Ltd., 2001. Report No. 4.
  • 57
    Peipert JF, Phipps MG. Observational studies. Clin Obstet Gynecol 1998; 41: 235–44.
  • 58
    The Medical and Health Research Council of The Netherlands. Treatment of recurrent Clostridium difficile infection with fecal therapy: the FECAL trial (Fecal enema to Eliminate Clostridium difficile Associated Longstanding diarrhea) (Project record). Den Haag, NL: The Medical and Health Research Council of The Netherlands (ZonMw), 2007.
  • 59
    Hota S. Oral Vancomycin followed by fecal transplant versus tapering oral Vancomycin. Available at: http://clinicaltrials.gov/ct2/show/NCT01226992. Accessed October 29, 2010.
  • 60
    Martin L. Modified fecal transplantation. J Clin Gastroenterol 2011; 45: 742.
View Full Article (HTML) Get PDF (153K)